Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | THRB | P10828 | 2/20 | 0.83 |
| ▸ | BLM | P54132 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | CTSL | P07711 | 1/20 | 0.73 |
| ▸ | CTSS | P25774 | 1/20 | 0.73 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.73 |
| ▸ | TDP2 | O95551 | 4/20 | 0.68 |
| ▸ | NSD2 | O96028 | 3/20 | 0.68 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.68 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.68 |
| ▸ | CES1 | P23141 | 2/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | S100A4 | P26447 | 6/20 | 0.57 |
| ▸ | CDC25B | P30305 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899280 | 0.93 | PTPRC (0.88) | PTPRCMEN1THRBBLMKMT2A | |
| SCHEMBL29566445 | 0.93 | PTPRC (0.88) | PTPRCMEN1THRBBLMKMT2A | |
| Bromide SCHEMBL28836578 | 0.91 | PTPRC (0.84) | PTPRCMEN1THRBBLMKMT2A | |
| Phanquone SCHEMBL462025 | 0.91 | MEN1 (1.00) | PTPRCMEN1THRBBLMKMT2A | |
| Phanquone SCHEMBL30956643 | 0.91 | MEN1 (1.00) | PTPRCMEN1THRBBLMKMT2A | |
| Phanquone SCHEMBL7633567 | 0.91 | MEN1 (1.00) | PTPRCMEN1THRBBLMKMT2A | |
| Phanquone SCHEMBL30659794 | 0.91 | MEN1 (1.00) | PTPRCMEN1THRBBLMKMT2A | |
| SCHEMBL29503833 | 0.86 | MEN1 (0.90) | PTPRCMEN1THRBBLMKMT2A | |
| SCHEMBL730769 | 0.86 | MEN1 (0.90) | PTPRCMEN1THRBBLMKMT2A | |
| SCHEMBL1103717 | 0.84 | GAA (0.78) | PTPRCMEN1THRBBLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117377329-A | Perovskite solar cell containing azaphenanthrenequinone additive | 中国科学院合肥物质科学研究院 | 2024-01-09 | — | — | CN | claimed |
| EP-1242086-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | EP | claimed |
| US-20030130298-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | US | claimed |
| EP-1242086-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001045680-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| CN-121405886-B | Phenanthrenequinone-based covalent organic framework material, nano preparation containing same, preparation method of phenanthrenequinone-based covalent organic framework material and biomedical application of phenanthrenequinone-based covalent organic framework material | 四川大学 | 2026-03-31 | — | — | CN | disclosed |
| CN-121405886-A | Phenanthrenequinone-based covalent organic framework material, nano preparation containing same, preparation method of phenanthrenequinone-based covalent organic framework material and biomedical application of phenanthrenequinone-based covalent organic framework material | 四川大学 | 2026-01-27 | — | — | CN | disclosed |
| CN-117843931-A | Azaquinone-based polymer material, and preparation method and application thereof | 井冈山大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117377329-A | Perovskite solar cell containing azaphenanthrenequinone additive | 中国科学院合肥物质科学研究院 | 2024-01-09 | — | — | CN | disclosed |
| CN-117377329-A | Perovskite solar cell containing azaphenanthrenequinone additive | 中国科学院合肥物质科学研究院 | 2024-01-09 | — | — | CN | disclosed |
| CN-117377329-A | Perovskite solar cell containing azaphenanthrenequinone additive | 中国科学院合肥物质科学研究院 | 2024-01-09 | — | — | CN | disclosed |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| EP-2024371-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134434-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
| EP-1242086-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| US-20030130298-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | US | disclosed |
| EP-1242086-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001045680-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | PTPRC 2968/4885MEN1 3762/4885THRB 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.